
Oncology Clinical Conversation Prep
Transform oncology trial data into compliant, high-impact talking points for HCP conversations.
What You Can Do
You convert raw clinical trial data, competitive intelligence, and patient population insights into concise, compliance-vetted talking points designed for high-stakes oncologist conversations. Claude helps you anticipate objections, address specific HCP resistance patterns, and build defensible clinical rationale for prescribing decisions—all within the time constraints of busy oncology practices.
Features
Transform complex trial data (efficacy, safety, mechanism of action) into clear clinical narratives that oncologists trust
Tailor talking points to an oncologist's patient demographics, treatment patterns, and formulary constraints
Generate pre-emptive responses to common oncologist concerns (resistance patterns, adverse events, cost-effectiveness)
Develop positioning around patient selection criteria, line-of-therapy rationale, and real-world outcome context
Ensure all talking points align with regulatory standards and substantiated clinical claims
Address competitive alternatives with evidence-backed clinical differentiation
Structure multi-point conversations that fit clinic or tumor board time windows
Example Output
For a new second-line lung cancer indication:
Primary Talking Point: "In your patient population with PD-L1 >50%, the Phase 3 KEYNOTE-407 data showed median OS improvement of 8.2 months vs. chemotherapy alone. That translates to ~70% of your eligible patients experiencing durable response beyond 6 months."
Anticipated Objection + Response: HCP concern: "Isn't grade 3+ immune toxicity a barrier?" "Yes, but the subset analysis in your patient cohort—adenocarcinoma, never-smokers—showed only 18% vs. 21% with chemo. Your tumor board actually flagged this as manageable within your existing checkpoint inhibitor protocols."
Competitive Differentiation: "Unlike [Competitor], our mechanism preserves antigen presentation, which explains the durability data in the ATLAS extension cohort (median 14-month follow-up)."
Patient Selection Guardrail: "Exclude patients with active autoimmune disease or recent steroids—your EHR shows you typically screen these at intake."
What's Included
- SKILL.md instruction file with oncology context and clinical conversation framework:
- HCP Practice Profile Template: worksheets to document oncologist prescribing patterns, patient populations, and objection hotspots
- Clinical Evidence Extraction Checklist: structure for pulling trial data, safety signals, and mechanism nuances into talking-point format
- Objection Response Framework: matrix mapping common oncologist concerns (efficacy, safety, cost, resistance) to evidence-backed counters
- 30-Minute Conversation Roadmap Template: time-boxed agenda for initial visits, new indication launches, or follow-up engagements
- Compliance Guardrails Checklist: verify talking points against regulatory substantiation and promotional standards
Who It's For
- Oncology Pharmaceutical Sales Reps preparing for material HCP interactions or territory visits
- Pharma Medical Science Liaisons needing to translate clinical trial evidence into HCP-friendly narratives
- Clinical Operations Teams building rep training materials and conversation standards
- Product Managers launching new oncology indications and refining messaging strategy
- Sales Managers coaching reps on evidence-based positioning and objection handling
Best For
- First-time territory visits to oncology practices (understanding treatment patterns, demographics, barriers)
- New indication launches (translating trial data into prescriber-ready positioning)
- High-value HCP meetings with top prescribers or KOLs (preparation within time constraints)
- Objection anticipation for resistance patterns specific to an oncologist's patient population
- Competitive differentiation in crowded indication spaces (mechanism, durability, safety trade-offs)
- Formulary/reimbursement conversations (addressing budget constraints and real-world cost-effectiveness)
- Tumor board presentations (distilling evidence into concise clinical rationale)







